FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for Fiscal Year 2020

Summary

The US Food and Drug Administration (FDA) has set the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2020, based on the average cost of reviewing priority review applications versus non-priority review applications from the previous year.